The investigational next-generation Guardant SHIELD assay has been designed to analyse nearly 20,000 epigenomic biomarkers, which help detect a broad range of solid tumours using a single blood test.
Presented at the American Association for Cancer Research Annual Meeting, the data demonstrated accuracy in detecting four cancer types, specifically colorectal, lung, pancreatic and bladder.
The assay also showed high accuracy in identifying tumour tissue of origin.
The company noted that the blood test showed 90% sensitivity in detecting colorectal cancer (CRC) and 87% in lung cancer during stages I and II.
The Guardant SHIELD assay also showed a sensitivity of 93% for both CRC and lung cancer for more advanced cancer stages III and IV.
For stages I and II, the test achieved 73% sensitivity for pancreatic cancer and 52% for bladder cancer.
The data also showed that the investigational assay achieved a sensitivity of 85% in bladder cancer and 84% in pancreatic cancer for advanced cancer stages III and IV.
Guardant Health co-CEO AmirAli Talasaz said: “These positive results show that the next-generation Guardant SHIELD multi-cancer assay provides sensitive detection of early-stage cancers with the ability to identify the tumour tissue of origin with high accuracy.
“Presentation of these positive results represents a major step forward in our commitment to offering clinicians and patients a highly sensitive blood-based multi-cancer screening test in select tumour types where we believe cancer screening can save lives.”
Last January, the company commenced the observational, prospective, multi-centre SHIELD Lung study, which has been designed to enrol individuals who are undergoing screening across several cancer types.
Approximately 10,000 individuals who are eligible for lung cancer screening will be enrolled in the first cohort, which will assess the Guardant SHIELD test’s performance in detecting lung cancer in high-risk individuals aged 50 to 80 years.